REPLIGEN CORP Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
REPLIGEN CORP (RGEN) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $5.08 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-03.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2017-08-03
- REPLIGEN CORP other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2017-06-30 was $4.05M.
- REPLIGEN CORP other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2017-03-31 was $1.03M.
- REPLIGEN CORP other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2016-12-31 was -$4.25M.
- REPLIGEN CORP other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2016-09-30 was -$312.00K.
- REPLIGEN CORP other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2016 was -$5.18M.
- REPLIGEN CORP other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2015 was -$2.79M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2017-06-30 | $4.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $5.08M 10-Q · filed 2017-08-03 | $825.00K derived: sum of 3 quarters · filed 2017-08-03 | $513.00K derived: sum of 4 quarters · filed 2017-08-03 |
| 2017-03-31 | $1.03M 10-Q · filed 2017-05-04 | -$3.22M derived: sum of 2 quarters · filed 2017-05-04 | -$3.53M derived: sum of 3 quarters · filed 2017-05-04 | |
| 2016-12-31 | -$4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$4.57M derived: sum of 2 quarters · filed 2017-02-23 | -$5.18M 10-K · filed 2017-02-23 | |
| 2016-09-30 | -$312.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$930.00K 10-Q · filed 2016-11-03 | ||
| 2016-06-30 | -$618.00K 10-Q · filed 2016-08-04 | |||
| 2015-12-31 | -$2.79M 10-K · filed 2017-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |